Comprehensive AI-powered diabetes care and complications prevention
Precision glucose management with intelligent complication prevention
SynThera empowers diabetes specialists with comprehensive AI support for all types of diabetes. Our platform integrates CGM data, insulin pump optimization, HbA1c trends, and complication screening to provide personalized treatment recommendations and prevent long-term complications.
Time in range improvement
Average HbA1c reduction
Hypoglycemia reduction rate
Retinopathy screening adherence
Real-time continuous glucose monitoring integration with pattern recognition, time-in-range optimization, and personalized glucose target recommendations.
Advanced algorithms for basal rate adjustments, insulin-to-carb ratios, and correction factors with hybrid closed-loop system integration.
Predictive algorithms for severe hypoglycemia risk with personalized alert systems and emergency protocol activation for high-risk patients.
Longitudinal glycemic control assessment with predictive modeling for future HbA1c values and treatment adjustment recommendations.
Early detection algorithms for DKA development with automated ketone monitoring integration and emergency intervention protocols.
Smart medication tracking with dosing reminders, side effect monitoring, and adherence pattern analysis for improved diabetes outcomes.
Patients achieving HbA1c targets
Time in range improvement
Severe hypoglycemia reduction
Complication screening adherence
A 28-year-old patient with Type 1 diabetes shows frequent glucose variability despite insulin pump therapy. SynThera analyzes CGM patterns, identifies dawn phenomenon, and recommends basal rate adjustments with carb ratio optimization.
AI Insight:
"Time in range 62%. Dawn phenomenon 4-8 AM with 40% glucose rise. Increase basal rate 5-8 AM by 0.05 units/hr. Consider hybrid closed-loop system upgrade."
A 55-year-old patient with Type 2 diabetes and cardiovascular disease needs treatment intensification. SynThera evaluates current medications, HbA1c trends, and comorbidities to recommend SGLT-2 inhibitor addition with GLP-1 agonist consideration.
AI Insight:
"HbA1c 8.4% on metformin alone. eGFR 65, history of MI. Add empagliflozin 10mg daily. Consider semaglutide if BMI >30. Monitor for volume depletion."
A 32-year-old pregnant patient at 26 weeks gestation develops gestational diabetes. SynThera creates personalized glucose targets, monitors fetal growth parameters, and provides postpartum diabetes screening protocols.
AI Insight:
"Fasting glucose 98 mg/dL, 2-hr postprandial 155 mg/dL. EFW 75th percentile. Start insulin if dietary modifications fail. Schedule OGTT 6-12 weeks postpartum."
Join diabetes specialists worldwide who are leveraging SynThera's comprehensive AI platform to improve glycemic control, prevent complications, and deliver personalized diabetes care with precision technology integration and evidence-based protocols.